Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q3 2025 Earnings Presentation
9 slides from Phibro Animal Health's earnings presentation, May 8, 2025
Slide 1: Phibro Animal Health Corporation Financial Results Fiscal Year 2025 Third Quarter
Phibro Animal Health Corporation Webcast and Conference Call May 8, 2025 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Financial Results Fiscal Year 2025 Third Quarter Ended March 31, 2025 May 8, 2025 Webcast and Conference Call
Slide 2: Important Information
Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels. All statements other than statements of historical or cur
Slide 3: Key Themes
Key Themes Strong FY2025 Full Year Continued Tariff Update Performance in Guidance (Including Momentum Animal Health Zoetis MFA) Q3 Total Consolidated sales and Q3 Total Animal Health sales While we are closely monitoring 2025 guidance adjusted EBITDA growth of 32% and adjusted EBITDA growth of the
Slide 4: Performance - Consolidated
Financial Performance - Consolidated Third Quarter, Year-on-Year comparison $ in millions, except per share data ▪ Year-On-Year % changes are in comparison to the same period of the prior fiscal year ▪ Adjusted results adjust GAAP results for one-off items, acquisition-related items and other (incom
Slide 5: Performance – Animal Health Legacy vs. New MFA
Financial Performance – Animal Health Legacy vs. New MFA Third Quarter, Year-on-Year comparison $ in millions Note: New MFA Business Adj. EBITDA is an estimate and includes only expenses fully dedicated to the New MFA business ▪ Year-On-Year % changes are in comparison to the same period of the prio
Slide 6: Performance – Other Segments
Financial Performance – Other Segments Third Quarter, Year-on-Year comparison $ in millions ▪ Year-On-Year % changes are in comparison to the same period of the prior fiscal year ▪ Adjusted results adjust GAAP results for one-off items, acquisition-related items and other (income) expense, including
Slide 7: Key Capitalization Metrics
Key Capitalization Metrics March 31, 2025 Free cash flow was $49 million for the TTM -- positive cash from operating activities (1) Free Cash Flow of $87 million, less capital expenditures of $(38) million. Cash and cash equivalents of $70 million (2) 3.0x gross leverage ratio; $734 million total de
Slide 8: Guidance – Phibro
Financial Guidance – Phibro Fiscal Year 2025 $ in millions, except earnings per share (EPS) data 8 May 8, 2025 Webcast and Conference Call
Slide 9: Q&A
PAHC Company Overview Q&A 9 May 8, 2025 Webcast and Conference Call